These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

115 related items for PubMed ID: 15110633

  • 1. Renal allograft protection with early angiotensin-converting enzyme inhibitors administration.
    Montanaro D, Gropuzzo M, Tulissi P, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
    Transplant Proc; 2004 Apr; 36(3):692-4. PubMed ID: 15110633
    [Abstract] [Full Text] [Related]

  • 2. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
    Montanaro D, Gropuzzo M, Tulissi P, Vallone C, Boscutti G, Mioni R, Risaliti A, Baccarani U, Adani GL, Sainz M, Bresadola F, Mioni G.
    Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
    [Abstract] [Full Text] [Related]

  • 3. Angiotensin-converting enzyme inhibitors after renal transplantation.
    Bravo P, Felgueiras J, Santos C, Oliveira C, Ponce P.
    Transplant Proc; 2008 Apr; 40(3):740-2. PubMed ID: 18455003
    [Abstract] [Full Text] [Related]

  • 4. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation.
    Heinze G, Mitterbauer C, Regele H, Kramar R, Winkelmayer WC, Curhan GC, Oberbauer R.
    J Am Soc Nephrol; 2006 Mar; 17(3):889-99. PubMed ID: 16481415
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow-up of ACE-inhibitor versus beta-blocker treatment and their effects on blood pressure and kidney function in renal transplant recipients.
    Suwelack B, Kobelt V, Erfmann M, Hausberg M, Gerhardt U, Rahn KH, Hohage H.
    Transpl Int; 2003 May; 16(5):313-20. PubMed ID: 12759722
    [Abstract] [Full Text] [Related]

  • 6. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic.
    Stiles KP, Abbott KC, Welch PG, Yuan CM.
    Clin Nephrol; 2001 Aug; 56(2):89-95. PubMed ID: 11522100
    [Abstract] [Full Text] [Related]

  • 7. Chronic allograft nephropathy and nephrotic range proteinuria.
    Ramanathan V, Suki WN, Rosen D, Truong LD.
    Clin Transplant; 2005 Jun; 19(3):413-7. PubMed ID: 15877807
    [Abstract] [Full Text] [Related]

  • 8. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
    Gutiérrez MJ, González E, Andrés A, Morales JM.
    Transplant Proc; 2009 Jun; 41(6):2348-50. PubMed ID: 19715916
    [Abstract] [Full Text] [Related]

  • 9. Risk factors and prognosis for proteinuria in renal transplant recipients.
    Sancho A, Gavela E, Avila A, Morales A, Fernández-Nájera JE, Crespo JF, Pallardo LM.
    Transplant Proc; 2007 Sep; 39(7):2145-7. PubMed ID: 17889119
    [Abstract] [Full Text] [Related]

  • 10. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 11. ACE inhibitors and angiotensin II antagonists in renal transplantation: an analysis of safety and efficacy.
    Stigant CE, Cohen J, Vivera M, Zaltzman JS.
    Am J Kidney Dis; 2000 Jan; 35(1):58-63. PubMed ID: 10620545
    [Abstract] [Full Text] [Related]

  • 12. The benefits of renin-angiotensin blockade in renal transplant recipients with biopsy-proven allograft nephropathy.
    Zaltzman JS, Nash M, Chiu R, Prasad R.
    Nephrol Dial Transplant; 2004 Apr; 19(4):940-4. PubMed ID: 15031353
    [Abstract] [Full Text] [Related]

  • 13. Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study.
    Evenepoel P, Claes K, Kuypers D, Maes B, Vanrenterghem Y.
    Nephrol Dial Transplant; 2005 Aug; 20(8):1714-20. PubMed ID: 15919696
    [Abstract] [Full Text] [Related]

  • 14. No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy--report from the ItalKid Project database.
    Ardissino G, Viganò S, Testa S, Daccò V, Paglialonga F, Leoni A, Belingheri M, Avolio L, Ciofani A, Claris-Appiani A, Cusi D, Edefonti A, Ammenti A, Cecconi M, Fede C, Ghio L, La Manna A, Maringhini S, Papalia T, Pela I, Pisanello L, Ratsch IM, ItalKid Project.
    Nephrol Dial Transplant; 2007 Sep; 22(9):2525-30. PubMed ID: 17526542
    [Abstract] [Full Text] [Related]

  • 15. Comparison of histopathological characteristics of allograft biopsy between responder and non-responder to antiproteinuric effect of angiotensin-converting enzyme inhibitor (ACEI).
    Namba Y, Moriyama T, Kyo M, Oka K, Kokado Y, Shi Y, Imamura R, Ichimaru N, Okuyama A, Takahara S.
    Clin Transplant; 2004 Sep; 18 Suppl 11():29-33. PubMed ID: 15191370
    [Abstract] [Full Text] [Related]

  • 16. Antiproteinuric efficacy of fosinopril after renal transplantation is determined by the extent of vascular and tubulointerstitial damage.
    Lufft V, Kliem V, Hamkens A, Bleck JS, Eisenberger U, Petersen R, Ehlerding G, Maschek H, Pichlmayr R, Brunkhorst R.
    Clin Transplant; 1998 Oct; 12(5):409-15. PubMed ID: 9787950
    [Abstract] [Full Text] [Related]

  • 17. Erythropoietin treatment in the sixth posttransplant month as a prognostic factor for renal allograft survival.
    Molina P, Gavela E, Sancho A, Avila A, Fernández-Nájera JE, Beltrán S, Crespo JF, Pallardó LM.
    Transplant Proc; 2006 Oct; 38(8):2441-4. PubMed ID: 17097961
    [Abstract] [Full Text] [Related]

  • 18. Study of ACEI versus ARB in managing hypertensive overt diabetic nephropathy: long-term analysis.
    Ozturk S, Sar F, Bengi-Bozkurt O, Kazancioglu R.
    Kidney Blood Press Res; 2009 Oct; 32(4):268-75. PubMed ID: 19776644
    [Abstract] [Full Text] [Related]

  • 19. Impact of chronic allograft nephropathy and subsequent modifications of immunosuppressive therapy on late graft outcomes in renal transplantation.
    Montagnino G, Banfi G, Campise MR, Passerini P, Aroldi A, Cesana BM, Ponticelli C.
    Nephrol Dial Transplant; 2004 Oct; 19(10):2622-9. PubMed ID: 15316096
    [Abstract] [Full Text] [Related]

  • 20. Fractional urinary excretion of IgG is the most powerful predictor of renoprotection by ACE inhibitors in IgA nephropathy.
    Bazzi C, Rizza V, Paparella M, Casellato D, Napodano P, Olivieri G, D'Amico G.
    J Nephrol; 2009 Oct; 22(3):387-96. PubMed ID: 19557716
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.